Resolvin D1 ameliorates inflammatory arthritis in mouse model

Rheumatoid arthritis (RA) is a debilitating autoimmune disorder that is characterized by the accumulation of inflammatory cells within the fluid of the joints.

Current therapeutic strategies mostly serve to ease pain and rarely are able to reverse damage or resolve inflammation.

A study in this issue of JCI Insight indicates that the lipid mediator resolvin D1 has anti-arthritic properties and should be further explored for treating RA.

A team led by Charles Serhan of Harvard Medical School and Mauro Perritti of Queen Mary University of London determined that resolvin D1 is elevated in joint fluid from both arthritic mice and patients.

Administration of resolvin D1 in mice with inflammatory arthritis dramatically reduced disease and promoted remission.

The authors determined that resolvin D1 promotes expression of genes associated with cartilage repair and reduces factors associated with joint damage.

The results of this study indicate that resolving D1 be further explored as a therapeutic strategy for treating RA.

Click the stars to rate this article

Resolvin D1 ameliorates inflammatory arthritis in mouse model

Public / Patient

Not yet rated

Health Professionals

Not yet rated

Ratings require JavaScript to be enabled.

Contact our news editors

For any corrections of factual information, or to contact our editorial team, please see our contact page.

Please note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms of use.

Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.

Be the first to comment

Leave a Reply

Your email address will not be published.


*